BiotechTube
Home/Glaukos/Robert (Bob) A. Kammer, M.D.
R(

Robert (Bob) A. Kammer, M.D.

Chief Medical Officer

Glaukos

Therapeutic Areas

GlaucomaCorneal DisordersRetinal Diseases

Glaukos Pipeline

DrugIndicationPhase
iStent inject® WPrimary Open-Angle GlaucomaCommercial
iStent infinite®Refractory Primary Open-Angle GlaucomaCommercial
iDose® TR (travoprost implant)Glaucoma / Ocular HypertensionCommercial Launch
iLink® V / EpioxaProgressive Keratoconus / Corneal EctasiaCommercial
Next-Gen MIGS DevicesGlaucomaDevelopment
Retinal Sustained-Drug Delivery PlatformRetinal Diseases (e.g., DME, RVO)Preclinical/Early Development

Leadership Team at Glaukos

TW
Thomas W. Burns
Chairman & Chief Executive Officer
JE
Joseph E. Gilliam
Chief Financial Officer
CC
Chris Calcaterra
Chief Commercial Officer
A(
Aleksandra (Ola) Sokolowski, Ph.D.
Chief Scientific Officer & SVP, Corporate Development
View full Glaukos profile